Synthesis, biological evaluation, and molecular modeling of 11H-indeno[1,2-b]quinoxalin-11-one derivatives and tryptanthrin-6-oxime as c-Jun N-terminal kinase inhibitors.

Abstract c-Jun N-terminal kinases (JNKs) play a central role in many physiologic and pathologic processes. We synthesized novel 11 H -indeno[1,2- b ]quinoxalin-11-one oxime analogs and tryptanthrin-6-oxime (indolo[2,1- b ]quinazoline-6,12-dion-6-oxime) and evaluated their effects on JNK activity. Several compounds exhibited sub-micromolar JNK binding affinity and were selective for JNK1/JNK3 versus JNK2. The most potent compounds were 10c (11 H -indeno[1,2- b ]quinoxalin-11-one O -(O -ethylcarboxymethyl) oxime) and tryptanthrin-6-oxime, which had dissociation constants (K d) for JNK1 and JNK3 of 22 and 76 nM and 150 and 275 nM, respectively. Molecular modeling suggested a mode of binding interaction at the JNK catalytic site and that the selected oxime derivatives were potentially competitive JNK inhibitors. JNK binding activity of the compounds correlated with their ability to inhibit lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) activation in human monocytic THP-1Blue cells and interleukin-6 (IL-6) production by human MonoMac-6 cells. Thus, oximes with indenoquinoxaline and tryptanthrin nuclei can serve as specific small-molecule modulators for mechanistic studies of JNK, as well as potential leads for the development of anti-inflammatory drugs. Graphical abstract Image 1 Highlights • New c-Jun N-terminal kinase (JNK) inhibitors were synthesized. • Compounds 10c and tryptanthrin-6-oxime were the most potent JNK inhibitors. • Compounds 6i , 10c , and tryptanthrin-6-oxime exhibited high selectivity for JNK1/JNK3 versus JNK2. • The active JNK inhibitors inhibited NF-κB/AP-1 activation and IL-6 production by human monocytic cells. [ABSTRACT FROM AUTHOR]